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Summary: 
Histologic classification of uterine smooth muscle tumors (USMTs) can be difficult for tumors with unusual 
combinations of increased mitotic rate, nuclear atypia, and geographic tumor necrosis. Typically, usual 
leiomyomas (ULM) have none of these features, and leiomyosarcomas (LMS) are defined by the presence of 
2/3 of these features. However, these are open to interpretation by the pathologist and many benign 
leiomyoma variants have been found to share some of these features.  
 
Here, we study a challenging case of a USMT that I encountered on a pathology elective with a drastically 
increased mitotic rate and questionable presence of geographic tumor necrosis, without nuclear atypia or 
architectural distortion, making a definitive assessment of this tumor's malignant potential difficult.  
 
We then reviewed the morphologic patterns of various USMTs, by examining a total of 10 tumors (12 
samples) from 8 separate patients, including our original case, and performed targeted next generation 
sequencing (NGS) to identify somatic alterations in formalin fixed paraffin embedded (FFPE) patient 
specimens. NGS revealed mutations in mediator complex subunit 12 (MED12) in ULM cases and deleterious 
mutations in the tumor suppressors tumor protein p53 (TP53) and retinoblastoma (RB1) in LMS cases.  
 
In addition, high-level copy number alterations (CNAs) were much more common in LMS cases, compared 
to ULM and leiomyoma variants, with the exception of one leiomyoma variant harboring a deep deletion of 
the fumarate dehydrogenase (FH) gene. Our original challenging case demonstrated a MED12 mutation 
without any additional CNAs, implicating a diagnosis of mitotically active leiomyoma and likely benign 
behavior. Given these findings, we propose a diagnostic schematic demonstrating utility for an integrated 
DNA/RNA profile to subtype diagnostically challenging USMTs. 
Methodology:  
The methodology of this project is outlined in detail in the manuscript draft uploaded below. In short, 12 
FFPE uterine smooth muscle tumor specimens from the UofM Pathology Tissue Archive were obtained. For 
each specimen, 3-6 punches of FFPE sections were obtained from a single representative block per case, by a 
board-certified pathologist (S.A.T.) to obtain minimal estimated tumor purity of 70%. DNA and RNA were 
coisolated using the Qiagen Allprep FFPE DNA/RNA kit (Qiagen) and the Qiagen QIAcube (Qiagen), 
according to the manufacturer’s instructions and were quantified using the Qubit 2.0 flurorometer (Life 
Technologies, Foster City, CA. Targeted multiplexed PCR based NGS was performed using a custom panel 
targeting 116 pan-cancer genes. Data analysis was was performed using in-house-developed, previously 
validated pipelines using Torrent suite 4.0.2, with alignment by TMAP and variant calling using the Torrent 
Variant Caller. To identify copy number alterations, normalized, GC-content corrected read counts per 
amplicon for each sample were divided by those from a pool of normal male genomic DNA samples (FFPE 
and frozen tissue, individual, and pooled samples), yielding a copy number ratio for each amplicon. Targeted 
mxPCR-based NGS of RNA was performed on coisolated RNA from all 12 UT samples (UT201-212) using 
a custom Ion Ampliseq panel assessing 155 target genes and 8 housekeeping genes (previously 103 target 
genes and 8 housekeeping) relevant for urothelial carcinoma. 
Results/Conclusion: 
Results and discussion are further detailed in the attached manuscript. Briefly, NGS revealed mutations in 
mediator complex subunit 12 (MED12) in ULM cases and deleterious mutations in the tumor suppressors 
tumor protein p53 (TP53) and retinoblastoma (RB1) in LMS cases.  
 
In addition, high-level copy number alterations (CNAs) were much more common in LMS cases, compared 
to ULM and leiomyoma variants, with the exception of one leiomyoma variant harboring a deep deletion of 
the fumarate dehydrogenase (FH) gene. Our original challenging case demonstrated a MED12 mutation 
without any additional CNAs, implicating a diagnosis of mitotically active leiomyoma and likely benign 
behavior. Given these findings, we also proposed a diagnostic schematic demonstrating utility for an 
integrated DNA/RNA profile to subtype diagnostically challenging USMTs. 
Reflection/Lessons Learned:  
In general, completing a CFI project forced me to take complete ownership of a project for the first time. I 
appreciated the process of creating my own research question and figuring out how to approach the 
investigating this question. Additionally, I learned how to interpret genomic data and how to write a 
manuscript. I learned how to understand the current level of research on a specific topic and how to use that 
to inform my research question and the writing of conclusions. I learned a lot about molecular pathology and 
the relationship between histologic pattern and the molecular landscape of a given tumor. This project made 
me more excited for my future in pathology and academic medicine. It definitely helped define my career 
goals and served as a great topic for residency interviews! 
 
